List view / Grid view
Depletion of ATP due to viral-induced CPE leads to a reduction in luminescence signal, enabling quantitation of viral-induced CPE in host cells.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
An exosome formulation has been created to deliver vascular endothelial-growth factor (VEGF) antibodies for choroidal neovascularisation therapy in models.
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
A non-invasive, label-free optical method can produce high-resolution imaging of cellular brain diseases in vivo.
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
A team have developed a minimally invasive exosome spray that helped repair rat hearts after myocardial infarction.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
US researchers used an AAV9 vector to edit a single base mutation in a prenatal mouse model, halting progression of Hurler syndrome.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer.
